slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 88,801-88,830
Pages 3,225
Rows per page 30
Component
88,801-88,830 of 96,741
06
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
07
The slide uses a donut chart to illustrate market growth from 2021 to 2028.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
34
The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant development strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
39
The slide uses a biological process diagram to illustrate the mechanism of action for three distinct drug candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
40
The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
42
The slide uses a process flow diagram to illustrate the clinical trial strategy for SPY001 and SPY003.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
45
The slide uses a comparative bar chart structure to validate the efficacy of genetic companion diagnostics (CDx) in improving clinical outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
49
The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
50
The table maps historical M&A deal values to Spyre's internal pipeline milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a series of icons to represent different scientific methodologies.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
56
The slide uses a scatter plot to show correlation between Cyno and Human half-lives, and bar charts to compare ADA (Anti-Drug Antibody) rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
68
This slide appears to be a screenshot of a website landing page.arm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank 1 hit
88
arm | IPO Presentation Deck | 117 slidesarm | IPO Presentation Deck | 117 slides · Arm
Pitch deck Investment bank 1 hit
06
The chart uses a line graph to show operating income over time, annotated with specific park attraction launches and a callout box comparing investment vs income growth.Disney | Investor Presentation Deck | 27 slides · Disney
Conference presentation Investor relations Beat · Interest1 hit
25
Uses a curved arrow diagram to represent a progression or portfolio of value drivers.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations Beat · Action1 hit
31
The slide uses a mathematical equation format to explain the revenue recognition process.Theravance Biopharma | Results Presentation Deck | 35 slides · Theravance Biopharma
Conference presentation Investor relations 1 hit
18
The chart uses a waterfall-like structure to bridge divisional performance to total group performance, highlighting the impact of integration-related expenses.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
20
The slide uses a combination of a data table for revenues/expenses and a waterfall chart for pre-tax income, with a callout box explaining the Corporate Center losses.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
26
The 2Q23 column shows a significant increase in total funding, reflecting the Credit Suisse acquisition.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Action1 hit
27
The slide uses stacked bar charts to show the composition of debt instruments (AT1, T2, Senior bonds HoldCo/OpCo) across different time periods.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Action1 hit
31
The slide uses a donut chart to show portfolio composition and a callout box to detail specific loan types and their collateralization status.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Action1 hit
36
Uses a waterfall-style bridge to compare asset and liability composition.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Action1 hit
05
The slide uses a four-column layout to delineate business units, each with a summary statement and bulleted strategic highlights.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Problem & Complication1 hit
24
Excludes Credit Suisse; includes footnote regarding seasonal tax payments.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Maturity Curve1 hit
39
The chart illustrates how Credit Suisse's 2Q23 AuM of 1,357bn is adjusted to reach 1,220bn in UBS invested assets.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
05
Vivid Seats | Investor Presentation Deck | 22 slidesVivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
12
The slide uses a combination of a bubble chart (representing market segments) and a bar chart (representing TAM growth).Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
16
The slide explains the dual-class structure (Class A and Class B) and how they relate to economic interest and EPS calculations.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations 1 hit
08
The slide highlights the growth of the skincare segment, showing both absolute revenue and percentage contribution to the total.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
09
The slide highlights a 13% YoY growth in combined net revenues for the three brands.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit